Skip to main content

Table 1 Summary of patients included in analysis

From: Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib

Trial Tumor type Treatment (s) n Frequency of Toxicity [n= (%)] Median PFS (months)
     HT ≥ grade 2 HFSR ≥ grade 2 HT < grade 2 vs. ≥ grade 2 Log-Rank P = HFSR < grade 2 vs. ≥ grade 2 Log-Rank P =
APC-CRPC mCRPC Bevacizuamb + Thalidomide + Docetaxel 60 15 (25.0) 4 (6.7) 14.9 vs. 31.5 0.0009 N/A* ND*
BAY-BEV ST Sorafenib + Bevacizumab 27 15 (55.6) 13 (48.1) 3.7 vs. 11.9 0.052 3.7 vs. 12.6 0.094
BAY-CRPC mCRPC Sorafenib 46 9 (19.6) 7 (15.2) 3.7 vs. 1.8 0.067 2.0 vs. 3.1 0.29
BAY-NSCLC NSCLC Sorafenib 22 9 (40.9) 10 (45.5) 1.9 vs. 4.6 0.19 2.9 vs. 3.7 0.38
BAY-CRC CRC Sorafenib + Cetuximab 18 1 (5.6) 2 (11.1) N/A* ND* 4.7 vs. 8.7 0.0065
BAY-KS KS Sorafenib +/- Protease inhibitor 8 3 (37.5) 2 (25.0) N/A* ND* N/A* ND*
  1. *Not done (ND). Patients were not evaluated in this analysis due to low frequency of toxicity (i.e. APC-CRPC vs. HFSR and BAY-CRC vs. HT) or due to limited PFS data (KS).
  2. 3 Patients participating on this trial were also treated on APC-CRPC.
  3. Two patients on BAY-KS trial received only sorafenib.
  4. C: Caucasian, AA: African-American, Others: Hispanic or Asians, mCRPC: metastatic castrate resistant prostate cancer, NSCLC: non-small cell lung cancer, CRC: colorectal cancer, KS: Kaposi's sarcoma, ST: solid tumors, HFSR: hand-foot skin reaction syndrome, NA: not applicable